The narrower loss and extended cash runway are positive, but the FDA's requirement for a second Phase 3 trial delays potential NDA submission and commercialization, increasing development costs and dilution risk. Monitor RECOVER-2 trial design and funding needs ahead of mid-2026 initiation.
Price Chart
Executive Summary
Reviva Pharmaceuticals reported financial results for 2025, showing a reduced net loss of $19.9M compared to $29.9M in 2024, with cash of $14.4M as of year-end. The company received FDA feedback requiring a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia, planned to start mid-2026, and raised $23M in cash through equity offerings, extending its runway into Q1-2027.
Key Financial Metrics
Key Facts
- Net loss narrowed to $19.9M in 2025 from $29.9M in 2024, with EPS improving from -$17.73 to -$5.48
- Cash and cash equivalents increased to $14.4M as of December 31, 2025, up from $13.5M in 2024
- FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine before NDA submission, delaying potential approval
- RECOVER-2 trial initiation planned for mid-2026, with U.S. enrollment expected to begin in Q3-2026
- Raised $23M in gross proceeds from three public offerings in 2025 and March 2026, giving ~$23M in cash post-March 2026 offering
Financial Impact
Reduced operating expenses by $10.6M YoY, primarily due to lower R&D spending; cash runway extended into Q1-2027
Risk Factors
- Clinical trial delay increases time to potential approval and risk of further regulatory hurdles
- Dilution risk remains elevated given reliance on equity financing and projected cash runway into only Q1-2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264432 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Press Release | $0.3521 $0.3521 | · 0.00% | ▲ +1.75% | $0.5000 (+42.01%) |
Jul 10, 2026 12w ago | 25-NSE | $0.6200 $0.4775 | ▲ +22.98% | ▲ +25.40% | $0.5000 (+19.35%) |
May 13, 2026 20w ago | Press Release | $0.3900 $0.6839 | ▼ −75.36% | ▼ −76.22% | $0.5000 (−28.21%) |
May 13, 2026 20w ago | 8-K | $0.3521 $0.7600 | ▼ −115.85% | ▼ −116.46% | $0.5000 (−42.01%) |
Apr 15, 2026 24w ago | 8-K | $0.8900 $0.8000 | ▼ −10.11% | ▼ −16.16% | $0.5000 (−43.82%) |
Mar 30, 2026 26w ago | Press Release | $0.6600 $0.8800 | ▲ +33.33% | ▲ +20.74% | $0.5000 (−24.24%) |
Mar 19, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▼ −2.41% | ▲ +5.21% | $0.5000 (+39.76%) |
Mar 18, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▲ +2.41% | ▼ −5.21% | $0.5000 (−39.76%) |
Mar 5, 2026 30w ago | 8-K | $4.20 $0.7200 | ▼ −82.86% | ▼ −79.07% | $0.5000 (−88.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access